Literature DB >> 2866634

Disposition of the psychotropic drugs buspirone, MJ-13805 and piribedil, and of their common active metabolite 1-(2-pyrimidinyl)-piperazine in the rat.

S Caccia, M H Fong, G Guiso.   

Abstract

1-(2-Pyrimidinyl)-piperazine (PmP) is a common metabolite of the structurally related drugs buspirone, MJ-13805 and piribedil. After i.v. injection (25 mumol/kg) to rats, all three parent drugs are rapidly cleared with a t 1/2 (beta) of about 30 min. The metabolite t 1/2 is about four times that of its parent drugs. About 25, 23 and 2% of buspirone, MJ-13805 and piribedil, respectively, reaches the systemic circulation as PmP. The metabolite concentrates in the brain where its A.U.C. is about twice those of buspirone and MJ-13805. Results indicate that PmP formation is a pharmacologically significant process for both buspirone and MJ-13805 but it is probably less important for piribedil.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2866634     DOI: 10.3109/00498258509045035

Source DB:  PubMed          Journal:  Xenobiotica        ISSN: 0049-8254            Impact factor:   1.908


  6 in total

1.  Mode of action of tiaspirone on the central cholinergic system.

Authors:  K Kolasa; E Palazzi; P Salmoiraghi; G Guiso; S Caccia; S Garattini; S Consolo
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1989-09       Impact factor: 3.000

2.  1-(2-pyrimidinyl)-piperazine may alter the effects of the 5-HT1A agonist in the learned helplessness paradigm in rats.

Authors:  P Martin
Journal:  Psychopharmacology (Berl)       Date:  1991       Impact factor: 4.530

3.  A metabolite of buspirone increases locus coeruleus activity via alpha 2-receptor blockade.

Authors:  G Engberg
Journal:  J Neural Transm       Date:  1989       Impact factor: 3.575

4.  Clinical pharmacokinetics of oral buspirone in patients with impaired renal function.

Authors:  S Caccia; G L Vigano; G Mingardi; S Garattini; R E Gammans; M Placchi; R F Mayol; M Pfeffer
Journal:  Clin Pharmacokinet       Date:  1988-03       Impact factor: 6.447

5.  Kinetics of piribedil and effects on dopamine metabolism: hepatic biotransformation is not a determinant of its dopaminergic action in rats.

Authors:  S Sarati; G Guiso; S Garattini; S Caccia
Journal:  Psychopharmacology (Berl)       Date:  1991       Impact factor: 4.530

Review 6.  Buspirone. A preliminary review of its pharmacological properties and therapeutic efficacy as an anxiolytic.

Authors:  K L Goa; A Ward
Journal:  Drugs       Date:  1986-08       Impact factor: 9.546

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.